Call Us Free: (800) 394-2767

Backed with $140M, startup launches three-pronged attack on liver diseases

Startup factory Third Rock Ventures is launching a three-pronged attack on liver diseases with $140 million and an unusually early and large assist from a Japanese drug maker.

Ambys Medicines Inc. will get $100 million from Takeda Pharmaceutical Co. Ltd. — including $80 million in research and development commitments — on top of $40 million from Third Rock to pursue cell therapy, gene therapy and traditional small-molecule approaches to restoring and replacing liver function lost in a variety…

Source link

Leave a Reply